Trump is edging toward a decision that could shatter decades of US drug policy. Powerbrokers are circling. Billionaires, pharma giants, crypto kings, and cannabis CEOs have all quietly taken their seats at the table. What he decides will hit prisons, Wall Street, and Main Street at once. And behind the scenes, one unanswered ques… Continues…
Donald Trump’s consideration of reclassifying marijuana comes at a moment when politics, money, and public opinion are colliding. After attending a $1 million-per-head fundraiser with cannabis executives and pharmaceutical power players, he publicly acknowledged that his administration is weighing whether marijuana should remain a Schedule I drug, the same category as heroin, or be downgraded to Schedule III. That shift wouldn’t legalize recreational use nationwide, but it would ease criminal penalties, unlock medical research, and hand cannabis companies long-sought tax relief, while opening the door for major pharmaceutical involvement.
Trump insists the issue is “very complicated,” torn between praise for medical use and warnings about broader social harm. He’s also operating in the shadow of Joe Biden’s stalled attempt to reclassify marijuana, inheriting both the political risk and opportunity. Whatever Trump decides, it will echo through courtrooms, boardrooms, and living rooms across America.